Protofibril-binding antibodies and their use in thereapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies

US8859501B2 · kind B2 · utility

Assignee

• BioArctic Neruoscience AB · SE

Inventors

• Eva Nordström · Vimmerby, SE
• Alex Kasrayan · Stockholm, SE
• Monica Ekberg · Stockholm, SE
• Valentina Screpanti Sundquist · Vilhelmina, SE
• Lars Lannfelt · Stockholm, SE
• Mats Holmquist · Sollentuna, SE

Key dates

• Filing date: Aug 1, 2013
• Grant date: Oct 14, 2014
• Expiry date: Aug 1, 2033

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/387
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Antibodies and fragments thereof have high affinity for human α-synuclein protofibrils and low binding of α-synuclein monomers, wherein the antibodies or fragments have specified Complementarity Determining Region (CDR) sequences. Compositions comprise such an antibody or fragment and methods of detecting α-synuclein protofibrils use such an antibody or fragment. In further embodiments, methods of preventing, delaying onset of or treating a neurodegenerative disorder with α-synuclein pathology comprise administering such an antibody or fragment, and such an antibody or fragment is used in the manufacture of a pharmaceutical composition for treatment of a neurodegenerative disorder with α-synuclein pathology. Such an antibody or fragment is used in the diagnosis or monitoring of the development of a neurodegenerative disorder with α-synuclein pathology, and in methods for reducing or inhibiting α-synuclein aggregation by administration of such an antibody or fragment.